Insider · CIK 0002075052
Joshua Bleharski
Files at IDYA (IDEAYA Biosciences, Inc.), SCTX (Scribe Therapeutics, Inc.). First filing -, latest -.
In brief
Joshua Bleharski files SEC Form 4 as CFO and director at IDYA (IDEAYA Biosciences, Inc.), and also at SCTX (Scribe Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Joshua Bleharski has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,725 | $0.00 | $0 | 14,725 | Jul 27, 2026 |
| Jan 30, 2026 | IDYA IDEAYA Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +170,000 | $0.00 | $0 | 170,000 | Feb 2, 2026 |
Questions about Joshua Bleharski
Answered from the filings on this page, as of the latest one.
Is Joshua Bleharski buying or selling?
Joshua Bleharski has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Joshua Bleharski's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joshua Bleharski has 0.
Where does Joshua Bleharski file Form 4?
Joshua Bleharski has filed Form 4 at IDYA (IDEAYA Biosciences, Inc.) as Chief Financial Officer; SCTX (Scribe Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.